You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Exon 20

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Fairfax, Virginia
    NEXT Virginia
Sep 18, 2023

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in

Recruiting
  • Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 21, 2023

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)

Recruiting
  • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 25, 2023

NSCLC Trial in Shanghai (Furmonertinib 160mg, Furmonertinib 240mg)

Recruiting
  • NSCLC
  • Furmonertinib 160mg
  • Furmonertinib 240mg
  • Shanghai, China
    Shanghai Chest hospital
Jan 16, 2023

NSCLC Trial in Winter Haven (Poziotinib, Docetaxel)

Suspended
  • NSCLC
  • Winter Haven, Florida
    Bond Clinic, P.A.
Jan 27, 2023

NSCLC Trial (Mobocertinib 160 mg)

Approved for marketing
  • Carcinoma, Non-Small-Cell Lung
  • Mobocertinib 160 mg
  • (no location specified)
Sep 28, 2022

EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma Trial in Houston (Poziotinib)

Recruiting
  • EGFR Exon 20 Mutation
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 12, 2022

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • NSCLC
  • (no location specified)
Jul 17, 2022

Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)

Recruiting
  • Lung Neoplasm Malignant
  • +18 more
  • Fairfax, Virginia
    New Experimental Therapeutics of Virginia (NEXT Oncology)
Mar 29, 2022

Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial (Poziotinib

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +3 more
  • Poziotinib Hydrochloride
  • 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE
  • (no location specified)
Jul 18, 2022

Mobocertinib in Adults With Lung Cancer in China (MEANING)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • No Intervention
  • Shanghai, China
    Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai J
May 9, 2023

Non-squamous NSCLC Trial (biological, drug, dietary supplement)

Not yet recruiting
  • Non-squamous NSCLC
  • Pembrolizumab
  • +7 more
  • (no location specified)
Feb 20, 2023

A Chart Review Study of Adults With Advanced NSCLC

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
    • (no location specified)
    Aug 1, 2022

    NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +5 more
    • Toripalimab
    • +3 more
    • Guanzhou, Guangdong, China
      Guangdong Lung Cancer Institute, Guangdong Provincial People's H
    Apr 4, 2023

    NSCLC Trial in Changsha (BEBT-109)

    Completed
    • NSCLC
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Aug 20, 2023

    NSCLC Trial in Worldwide (Afatinib)

    Completed
    Has Results
    • NSCLC
    • Köln, Germany
    • +4 more
    Aug 23, 2022

    Learn About Tests Looking forGene Mutation in Lung Cancer in

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • No Intervention
    • Beijing, China
      Department of Pathology, National Cancer Center/National Clinica
    Feb 24, 2023

    Locally Advanced or Metastatic NSCLC Trial in Seoul (Osimertinib 80 MG [Tagrisso])

    Completed
    • Locally Advanced or Metastatic NSCLC
    • Osimertinib 80 MG [Tagrisso]
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Sep 22, 2021

    NSCLC Trial in Shanghai (Furmonertinib 240mg, Furmonertinib 160mg)

    Withdrawn
    • NSCLC
    • Furmonertinib 240mg
    • Furmonertinib 160mg
    • Shanghai, China
      Shanghai Chest hospital
    Oct 17, 2021

    Locally Advanced or Metastatic NSCLC, EGFR Exon20 Insertion Mutations Trial (JMT101, Osimertinib Mesylate Tablets)

    Not yet recruiting
    • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    • EGFR Exon20 Insertion Mutations
    • JMT101
    • Osimertinib Mesylate Tablets
    • (no location specified)
    Nov 12, 2021

    NSCLC Trial in Qingdao (Osimertinib Oral Tablet)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Osimertinib Oral Tablet
    • Qingdao, Shandong, China
      Qingdao Central Hospital, Qingdao Cancer Hospital
    Nov 1, 2021

    Non-small Cell Lung Cancer EGFR Exon 20 Insertion

    Recruiting
    • Non-small Cell Lung Cancer (NSCLC)
      • Cordoba, Andalucia, Spain
      • +14 more
      Nov 1, 2022

      NSCLC Trial in Amsterdam, Groningen, Maastricht (Afatinib, Cetuximab)

      Recruiting
      • Carcinoma, Non-Small-Cell Lung
      • Amsterdam, North-Holland, Netherlands
      • +3 more
      Oct 19, 2021

      Non Small Cell Lung Cancer, EGFR Exon 20 Mutation Trial in Worldwide (CLN-081)

      Recruiting
      • Non Small Cell Lung Cancer
      • EGFR Exon 20 Mutation
      • Duarte, California
      • +18 more
      Nov 11, 2022

      NSCLC Trial in China (DZD9008)

      Active, not recruiting
      • Non-Small Cell Lung Cancer
      • Beijing, China
      • +32 more
      Jan 26, 2023